WIGGINS v. LABORATORY CORPORATION OF AMERICA HOLDINGS

CourtDistrict Court, E.D. Pennsylvania
DecidedOctober 11, 2024
Docket2:24-cv-00648
StatusUnknown

This text of WIGGINS v. LABORATORY CORPORATION OF AMERICA HOLDINGS (WIGGINS v. LABORATORY CORPORATION OF AMERICA HOLDINGS) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
WIGGINS v. LABORATORY CORPORATION OF AMERICA HOLDINGS, (E.D. Pa. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

MICHAEL WIGGINS AND TERI CIVIL ACTION STEVENS, Plaintiffs,

v. NO. 24-0648 LABORATORY CORPORATION OF AMERICA HOLDINGS, Defendant.

MEMORANDUM OPINION

Plaintiffs Michael Wiggins and Teri Stevens have sued the healthcare company Laboratory Corporations of America Holdings (“LabCorp”), alleging on behalf of a putative class of similarly situated customers that LabCorp shared sensitive patient health information with Google in violation of, inter alia, the Electronic Communications Privacy Act, 18 U.S.C. § 2510, et. seq. Relying on the Federal Arbitration Act (“FAA”), 9 U.S.C. § 2 et seq., LabCorp now moves to compel individual arbitration and stay this action pending the outcome of those proceedings. For the reasons that follow, LabCorp’s Motion will be granted. I. BACKGROUND A. Plaintiffs’ Interactions with LabCorp’s Website LabCorp is a provider of clinical laboratory services headquartered in Burlington, North Carolina. The company offers a patient portal on its website, which enables users to, among other things, schedule medical tests, review the results of those tests, and pay bills. To receive access to the patient portal, users must first register on LabCorp’s website and provide certain information, such as their name, date of birth, mailing address, phone number, and email address. Users must also check a box towards the bottom of the registration screen (underneath a heading marked “Authorization”) affirming that they “have read, understand and agree to the LabCorp Terms of Use and Web Privacy Statement.” This affirmation appears in text adjacent to the checkbox. As of 2019, the phrases “Terms of Use” and “Web Privacy Statement” are written in blue text—which stands in contrast to the white background and surrounding black text on the rest of the account registration screen—and are designed to operate as clickable hyperlinks that

take the user to the relevant document. Stevens and Wiggins created accounts on the LabCorp patient portal in 2019 and 2022 respectively and, in doing so, checked the box in the “Authorization” section. However, they did not: (1) read the text adjacent to the checkbox, which they characterize as “tiny” and “barely legible”; (2) attempt to click the phrases written in blue text to determine whether they were functioning hyperlinks; (3) read any of the provisions that may have appeared on the landing pages associated with those hyperlinks; or, (4) understand what any of it meant. Rather, they “just checked these boxes because that’s what everyone knows you have to do to get to the next page on a website.” Plaintiffs describe a similar interface with a pop-up window on the patient portal in May

2023. At the time they and other users logged into the patient portal for the first time the system displayed a pop-up window alerting them of an “IMPORTANT UPDATE” related to “Changes to [LabCorp’s] Patient Portal User Agreement.” Immediately below this text, LabCorp informed users that it had “recently updated [its] Patient Portal User Agreement,” which they could review at “anytime on [its] website.” At the bottom of the pop-up window, there was a blue oblong button with the text, “Review Agreement,” written in white typeface. The button was designed to operate as a clickable hyperlink that would take the user to the agreement. Alternatively, users could close the pop-up window by clicking the “X” in the top-right corner, which is what Plaintiffs concede they did after being confronted with the alert.1 B. The Terms of Use LabCorp states that the “Terms of Use” hyperlink on the account registration screen was designed to direct users to its then-operative user agreement (the “User Agreement”). Both iterations of the User Agreement that were in effect when Wiggins and Stevens registered for the patient portal provided that users “agree to be bound by this agreement when you click ‘I agree’

and/or continue to access or use the Patient Portal. If you do not understand or agree to be bound by this agreement, do not access or use the Patient Portal.” Among the terms laid out in the User Agreement is a mandatory arbitration provision, which users are advised, in bold, “requires the use of arbitration on an individual basis and limits the remedies available to you in the event of disputes or claims in connection with this Agreement or the Patient Portal.” Specifically, the arbitration provision, which is included in all capital letters, states that “any dispute, claim or controversy arising out of or relating in anyway to this Agreement or the Patient Portal shall be finally decided by binding arbitration under the Consumer Arbitration Rules of the American Arbitration Association [the “AAA Rules”].” The

AAA Rules, in turn, empower the arbitrator to, among other things: (1) “rule on his or her own jurisdiction, including any objections with respect to the existence, scope, or validity of the arbitration agreement or to the arbitrability of any claim or counterclaim”; and, (2) “determine the existence or validity of a contract of which an arbitration clause forms a part.” Additionally, the User Agreement included a class action waiver, which stated that the

1 In their respective declarations, Wiggins and Stevens both aver that they “do not remember seeing this pop-up box, clicking any button in it, or reviewing any agreement it might have linked to” and did not understand that by “clicking the ‘X’ to close the window meant they were agreeing to anything.” Nonetheless, they acknowledge that they “know now that the pop-up box had an ‘X’ at the top right corner to close it out” and are “confident that this is what [they] did because that is what everyone knows you do to close a pop-up window.” Any ambiguity in Plaintiffs’ actions with respect to closing the pop-up window is clarified in a subsequent section when they both admit to having “just clicked the ‘X’ to close the pop-up box.” parties “may bring claims against the other only in your or its individual capacity, and not as a plaintiff or class member in any purported class or representative proceeding.” It also set forth a change-of-terms provision advising users that LabCorp “may, at any time and from time to time, supplement, amend, or otherwise change this Agreement.”

Finally, the User Agreement contained an integration clause, providing that “[t]his Agreement, the Terms and Conditions, and any other policies or notices referenced herein, represent the entire agreement of the parties with respect to the subject matter hereof.” Given that various provisions of the User Agreement are “incorporated herein via hyperlink,” users agree that “if at the time of accepting this Agreement such hyperlinks do not redirect you to the appropriate web page, you will notify LabCorp immediately” via email. “Failure to notify LabCorp immediately shall be deemed as acceptance of the provisions incorporated herein by hyperlink as though they redirected you to the appropriate webpage.” On May 9, 2023, LabCorp issued a modified version of the User Agreement (the “Modified Agreement”) and alerted users through the pop-up window described above. The

Modified Agreement included a near-identical arbitration provision and class action waiver, which, in relevant part, reads as follows: Arbitration Agreement. You and LabCorp mutually agree, to the fullest extent of the law, that any Dispute (defined below) shall be arbitrated and finally decided by binding arbitration administered by the American Arbitration Association . . . under its Consumer Arbitration Rules . . . except as modified below or otherwise agreed to.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
First Options of Chicago, Inc. v. Kaplan
514 U.S. 938 (Supreme Court, 1995)
Roth v. NORFALCO LLC
651 F.3d 367 (Third Circuit, 2011)
Kpmg LLP v. Cocchi
132 S. Ct. 23 (Supreme Court, 2011)
Kirleis v. Dickie, McCamey & Chilcote, P.C.
560 F.3d 156 (Third Circuit, 2009)
Johnston County v. R. N. Rouse & Co.
414 S.E.2d 30 (Supreme Court of North Carolina, 1992)
Northington v. Michelotti
464 S.E.2d 711 (Court of Appeals of North Carolina, 1995)
Hines v. Overstock. Com, Inc.
668 F. Supp. 2d 362 (E.D. New York, 2009)
McNeil v. City of Easton
694 F. Supp. 2d 375 (E.D. Pennsylvania, 2010)
Kevin Nguyen v. Barnes & Noble Inc.
763 F.3d 1171 (Ninth Circuit, 2014)
Flintkote Co. v. Aviva PLC
769 F.3d 215 (Third Circuit, 2014)
Bobbie James v. Global TelLink Corp
852 F.3d 262 (Third Circuit, 2017)
Henry Schein, Inc. v. Archer & White Sales, Inc.
586 U.S. 63 (Supreme Court, 2019)
Cathy Bowles v. OneMain Financial Group, LLC
954 F.3d 722 (Fifth Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
WIGGINS v. LABORATORY CORPORATION OF AMERICA HOLDINGS, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wiggins-v-laboratory-corporation-of-america-holdings-paed-2024.